Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease

Ilan Goldenberg, Arthur J. Moss*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Patients with ischemic left ventricular dysfunction are at a high risk for ventricular tachyarrhythmias and sudden cardiac death. Randomized clinical trials have demonstrated that pharmacologic management with antiarrhythmic drugs has limited efficacy for the prevention of arrhythmic mortality in this high-risk population, whereas the implantable cardioverter defibrillator (ICD) has significant life-saving benefit in primary and secondary prevention trials. However, secondary analyses of these studies have identified some limitations of the ICD in subsets of patients with coronary artery disease, including limited defibrillator efficacy early after coronary revascularization and acute myocardial infarction. We review current knowledge from primary and secondary prevention clinical trials regarding the benefit and limitations of the ICD in high-risk patients with coronary artery disease.

Original languageEnglish
Pages (from-to)79-93
Number of pages15
JournalCardiac Electrophysiology Clinics
Issue number1
StatePublished - Jan 2009
Externally publishedYes


  • Coronary artery disease
  • Implantable cardioverter defibrillator
  • Primary prevention
  • Secondary prevention
  • Sudden cardiac death


Dive into the research topics of 'Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease'. Together they form a unique fingerprint.

Cite this